The widely used cancer drug bevacizumab may cause severe loss of protein from the kidney into the urine that can lead to significant kidney damage and can compromise the efficacy of cancer treatment, according to a new study. The results suggest that physicians should monitor patients' kidney health when prescribing this angiogenesis inhibitor.